samedan logo

 
 
spacer
home > ebr > winter 2003 > contract manufacturing for small biotechs
PUBLICATIONS
European Biopharmaceutical Review

Contract Manufacturing for Small Biotechs

Much has been written recently about the burgeoning growth of biopharmaceutical business and the looming capacity crunch in biologics manufacture. Numerous enterprises are investing heavily in the production of stainless steel so that they are positioned to churn out lucrative, premium-priced biopharmaceuticals that are already approved or forecast to be approved in the coming years. The emergence of biopharmaceuticals as effective therapeutics, coupled with a trend to outsource biologic manufacturing, has led to unprecedented growth in 'third party' contract manufacturing organisations (CMOs) and much of the additional capacity will come from that sector. Here in Canada for example, a €100 million expansion to provide 60,000L of animal cell culture capability has recently been announced by DSM Biologics.

Many of the CMOs are positioning themselves to capture the long-term, large-volume supply contracts offered by big pharma or big biotech that are more lucrative than the high-risk developmental projects typical of smaller, early-stage biotech companies trying to get their products into the clinic for the first-in-man trials. Due to the high risk of failure for early-stage biotech projects, the chances of them eventually leading to long-term supply agreements are relatively small.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr David Cox, PhD, CEO of KS Avicenna Inc

Dr David Cox is CEO of KS Avicenna Inc, a cGMP contract manufacturer of fermentation-derived biologies. He has more than 25 years of experience in the biotechnology and pharmaceutical industries in both the UK and Canada. Prior to his appointment with KS Avicenna, Dr Cox was CEO of Synsorb Biotech Inc, a publicly traded biotech company listed on the TSE and Nasdaq. Dr Cox's experience also includes CEO of Apotex Fermentation Inc and VP Advanced Technologies for the Alberta Research Council.

spacer
Dr David Cox
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drive for generics sees Korea increasingly attractive to international pharma

Amsterdam, 31st July 2019: Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement